Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-
drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially …

Background The Médecins Sans Frontières Clinic in Mumbai, India, has been providing
concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with …

Background Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain
low globally. Availability of newer drugs has given scope to develop regimens that can be …

Background There are scarce data on the clinical outcomes of persons retreated with
new/companion anti-tuberculosis (TB) drugs for multidrug-and rifampicin-resistant …

The World Health Organization (WHO) estimated that 490 000 cases of multidrug-resistant
(MDR) tuberculosis (TB)(defined as TB caused by Mycobacterium tuberculosis strains …

Objectives The objective of this study was to evaluate the efficacy and safety of the
sequential use of bedaquiline (Bdq) and delamanid (Dlm) in patients with multidrug-resistant …

Background At a time when programs were struggling to design effective regimens for the
treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of …

There are limited data on combining delamanid and bedaquiline in drug-resistant
tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV …

Background This retrospective cohort study assessed benefits and risks of bedaquiline
treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating …

Background Bedaquiline and delamanid have been approved for treatment of multidrug-
resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns …